These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27797623)

  • 1. Making the most of every option in the treatment of ovarian cancer.
    du Bois A
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):1. PubMed ID: 27797623
    [No Abstract]   [Full Text] [Related]  

  • 2. Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
    Poveda A; Marth C
    Future Oncol; 2017 Oct; 13(23s):11-16. PubMed ID: 29020823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
    Dear RF; Gao B; Harnett P
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory and recurrent ovarian cancer.
    Alberts DS
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):8-14. PubMed ID: 10071969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in gynecologic cancers: Ready for prime time?
    Seoud M; Lundqvist EÅ; Fujiwara K
    Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 2():S150-2. PubMed ID: 26433672
    [No Abstract]   [Full Text] [Related]  

  • 8. New drugs in ovarian cancer.
    Fleming GF
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
    Fujiwara K
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():354-8. PubMed ID: 10895180
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.
    González-Martín A; du Bois A
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):3-10. PubMed ID: 27797624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 as a molecular drug target in ovarian cancer.
    Farra R; Dapas B; Grassi M; Benedetti F; Grassi G
    Expert Opin Ther Targets; 2019 Mar; 23(3):161-164. PubMed ID: 30724632
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the chances for platinum-sensitive ovarian cancer patients.
    González A
    Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
    Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of molecular classification on clinical management of ovarian cancer].
    Hasegawa K
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):166-8. PubMed ID: 25834913
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Colombo N
    Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment and clinical trials in ovarian cancer.
    Han LY; Kipps E; Kaye SB
    Expert Opin Investig Drugs; 2010 Apr; 19(4):521-34. PubMed ID: 20367193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer: is dose intensity dead?
    Ozols RF
    J Clin Oncol; 2007 Sep; 25(27):4157-8. PubMed ID: 17698802
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer.
    Teo MC
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):3-8. PubMed ID: 24247932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veliparib for the treatment of ovarian cancer.
    Bogliolo S; Cassani C; Dominoni M; Musacchi V; Venturini PL; Spinillo A; Ferrero S; Gardella B
    Expert Opin Investig Drugs; 2016; 25(3):367-74. PubMed ID: 26807493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.